We evaluated the molecular mechanism of resistance in herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) gene-transfected murine mammary carcinoma (FM3ATK − /HSV-1 TK + ) cells, that were selected for resistance against (E)-5-(2-bromovinyl)-2Ј-deoxyuridine (BVDU) and ganciclovir (GCV) by prolonged exposure of the cell cultures to dose-escalating concentrations of these compounds. Drug-resistant FM3ATK − /HSV-1 TK + cells showed marked differences in their sensitivity spectrum to a series of antiherpetic nucleoside analogues. BVDU-resistant FM3ATK − /HSV-1 TK + cells displayed the same sensitivity profile as wild-type FM3A/0 cells. In contrast, GCV-resistant
Introduction
Due to its broad substrate specificity, herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) is able to phosphorylate a wide range of nucleoside analogues including the acyclic guanosine analogue ganciclovir (GCV) and the thymidine analogue (E)-5-(2-bromovinyl)-2Ј-deoxyuridine (BVDU). This important feature of HSV-1 TK has, for the last two decades, been exploited in the selective therapy of herpesviral disease. 1 Indeed, antiherpetic nucleoside analogues are selectively phosphorylated in herpesvirus-infected cells, resulting in potent inhibition of viral DNA synthesis and thus viral replication. The HSV-1 TK gene is now also utilized in the combined gene/chemotherapy of cancer. Tumor cells can selectively be sensitized to the growth inhibitory effects of antiherpetic nucleoside analogues upon transfection with the HSV-1 TK gene. [2] [3] [4] [5] [6] Several clinical trials have demonstrated the potential usefulness of this revolutionary approach in patients, although the technique still needs marked improvements. 7 Cancer therapy aims to eliminate all tumor cells of a particular tumor mass. However, frequently some tumor cells evade the toxic effects of therapy and eventually grow out to produce a recurrent tumor. Elucidation of the mechanism of such resistance is important to improve the efficacy of cancer therapy approaches in the clinical setting. We reported previously that the antiherpetic nucleoside analogues (E)-5-(2-bromovinyl)-2Ј-deoxyuridine (BVDU) and ganciclovir (GCV) are extremely potent inhibitors of the proliferation of the HSV-1 TK genetransfected murine mammary carcinoma cells (designated FM3ATK − /HSV-1 TK + ). [2] [3] [4] [5] The latter cell line was derived from FM3ATK − cells lacking cytosolic TK, upon transfection with the HSV-1 TK gene. 8 Interestingly, the FM3ATK − cells were more sensitive to the cytostatic activity of BVDU, (E)-5-(2-iodovinyl)-2Ј-deoxyuridine (IVDU) and (E)-5-(2-bromovinyl)-2Ј-deoxycytidine (BVDC), but not to GCV and other antiherpetic nucleoside analogues, than the corresponding wild-type FM3A/0 cells. 9 In this study, FM3ATK − /HSV-1 TK + cells were exposed to dose-escalating concentrations of BVDU and GCV and were eventually able to grow in the presence of 20 m BVDU or 80 m GCV. The sensitivity/resistance spectrum to antiherpetic drugs has been determined, and the molecular basis of the drug resistance revealed. + cell lines cannot account for the marked differences in drug susceptibilities that were acquired by these cell lines.
Results

Selection of FM3ATK
Cytostatic activity of antiherpetic compounds against wild-type and drug-resistant FM3A cell lines Four pyrimidine nucleoside analogues including BVDU and its closely related derivatives IVDU, BVDC, and 4Ј-Thio-BVDU, and four purine nucleoside analogues including GCV, PCV, BCV and ACV ( . The results are shown in Table 1 . The 50% inhibitory concentrations of the compounds for the proliferation of FM3A/0, FM3ATK − and FM3ATK − /HSV-1 TK + cells had been determined before [2] [3] [4] [5] 11 but were repeated to exclude experimental variation and to allow side-by-side comparison of the inhibitory effects of the drugs on the parental and drug-resistant cell lines. From Table 1 , it is clear that none of the pyrimidine and purine nucleoside analogues were markedly inhibitory to the proliferation of wild-type FM3A/0 cells. The cytostatic activity of the pyrimidine nucleoside analogues ranged from 16 to 242 m, and for the guanosine derivatives between 208 and 500 m, depending on the nature of the compound. BVDU, IVDU and BVDC, but not the purine nucleoside analogues, showed a moderately increased inhibitory effect (10-to 50-fold) on the proliferation of 
FM3ATK
− cells. In contrast, all pyrimidine and purine nucleoside analogues showed a strongly increased cytostatic potential against HSV-1 TK gene-transfected FM3A cells. The pyrimidine nucleosides displayed IC 50 -values that were 400 to 7000-fold lower than the concentrations required to inhibit the proliferation of wild-type FM3A/0 cells. Also the purine nucleoside analogues, in particular Gene Therapy GCV and PCV, showed a markedly increased inhibitory potential against FM3ATK − /HSV-1 TK + cells (Ͼ50-to 100-fold), but they were, however, significantly less cytostatic to the HSV-1 TK gene-transfected cells than the pyrimidine nucleoside analogues ( Table 1) .
The two FM3ATK − /HSV-1 TK + cell lines that were selected under BVDU pressure (final concentration: 20 m) proved highly resistant to BVDU in our proliferation assays. In addition, both cell lines were cross-resistant to all pyrimidine and purine nucleoside analogues that were evaluated. In fact, FM3ATK (Table 1) . Apparently, the number and magnitude of the dose-escalation steps that were used to select both BVDU-resistant cell lines had not affected their sensitivity to the antiherpetic drugs.
The 
/GCV
R/L cells were still sensitive to the cytostatic effect of BVDU, IVDU and BVDC, thereby displaying a sensitivity profile that was essentially the same as that of the (TK-deficient) FM3ATK
− cell line. It should be noted that the sensitivity profile of the various drug-resistant cell lines remained exactly the same after 3 months of cultivating the mutant cells in the absence of drug pressure, indicating that the induced resistant phenotypes were stable and not transient. In addition to the Southern blot analysis, a PCR experiment was performed on total cellular DNA of all cell lines, using primers at the 5Ј and 3Ј end of the HSV-1 TK gene, assuring that, under the same conditions, comparable amounts of the control ␤-actin fragment were produced. It is clear from Figure 4b cells. 12, 13 Therefore, cellular DNA form the wild-type and drug-resistant FM3ATK − /HSV-1 TK + cell lines was digested with BamHI and either MspI or HpaII, and subjected to Southern blotting. MspI and HpaII constitute an isoschizomer restriction enzyme pair (recognizing the sequence CC*GG). HpaII is methylation-sensitive while MspI can cleave the sequence even when it is methylated at the internal C. As is evident from − cells in the presence of escalating BVDU concentrations for 6 weeks (Figure 8 , panels a and b, respectively). The cytostatic effect of a series of antiherpetic nucleoside analogues and a series of antimetabolites against these resistant cell lines was determined, as summarized in in HSV-1 TK-expressing transgenic mice, Moolten et al 14 observed that five out of six recurrent lymphomas after GCV therapy had lost the herpes TK gene. Deleted TK gene sequences were also demonstrated in 10 out of 12 GCV-resistant clones in vitro after GCV treatment of HSV-1 TK gene-transfected sarcoma cells. 15 Partial or complete loss of the HSV-1 TK gene was noted in gastrointestinal tumor cells transduced with recombinant retroviral vectors containing the HSV-1 TK gene, upon prolonged treatment with GCV. In this case, however, the lack of TK gene sequences was apparently due to partial or complete deletion of the TK gene in a fraction of the retroviral vector preparation that was used to transduce the tumor cells with the herpetic TK gene. 16 Golumbek and colleagues 17 investigated the use of the HSV-1 TK gene as a suicide gene to eliminate live tumor cell vaccines. They demonstrated that tumors that recurred after drug treatment were as sensitive to GCV as the parental tumor cell line, indicating that some cells had escaped the GCV treatment, presumably due to a temporary exit from the cell cycle during drug exposure. 17 Thus, resistance towards GCV often seems to be associated with HSV TK gene loss. In contrast, the FM3ATK 
R/L cells. Thus, the mechanism of resistance observed in our drug-resistant tumor cell lines differs from that described earlier by Moolten et al 15 , Yang et al 16 and Golumbek et al. 17 We could however not reverse the drug-resistant phenotypes by treatment with the demethylating agent 5-azacytidine. 12, 13 Indeed, the cytostatic activity of BVDU and GCV was redetermined after pre-incubation of the cells with the demethylating agent 5-azacytidine. The resistant phenotypes were not influenced by 3 days of pre-incubation with 5-azacytidine at a concentration of 0.25 m. This was the highest possible 5-azacytidine concentration without growth inhibitory effect on the wild-type and drug-resistant FM3ATK − /HSV-1 TK + cell lines. Similary, a 24 h pre-incubation period in the presence of a more toxic 5-azacytidine concentration (ie 5 m) did not result in increased sensitivity to GCV or BVDU (data not shown). Although in both BVDU-and GCV-resistant tumor cell lines, the mechanism of drug resistance seemed similar, a remarkable difference in drug sensitivities was observed when a series of pyrimidine and purine nucleoside analogues were evaluated for their cytostatic effects against the FM3A/0, FM3ATK Table 1) . The FM3ATK − cell line was constructed by mutagenization of FM3A/0 cells with N-methyl-NЈ-nitro-NЈ-nitrosoguanidine and subsequent selection in medium containing 5-bromo-2Ј-deoxyuridine. 8 This cell line was found deficient in cytosolic TK. BVDU, IVDU and BVDC were previously shown to have a markedly increased cytostatic activity against the TK − cell lines derived not only from murine mammary carcinoma FM3A/0 (ie FM3ATK − ), but also from murine leukemia (L1210) and murine fibroblast (LM) cells. 9, 18, 19 No significant differences between the murine TK + and TK − cell lines were noted with regard to the inhibitory effects of BVDU and IVDU on either thymidylate synthase activity, or DNA, RNA or protein synthesis, or − and L1210/TK − cells. 9 The phenomenon seems to be specific for murine cell lines, as human TK-deficient osteosarcoma (OstTK (Table 2) do not argue for a marked change in nucleotide metabolism. FdU, requiring cytosolic thymidine kinase activity in order to exert a cytostatic effect, was able to inhibit FM3A/0 cell proliferation, but not the proliferation of FM3ATK − and FM3ATK − /BVDU R cells (Table 2 ). This indicates that the FM3ATK − /BVDU R cell lines did not just gain a functional cytosolic TK. This is in accordance with the Southern blot experiments performed by Ayusawa et al, 8 suggesting that the FM3ATK − cell line corresponded to a (cytosolic TK) deletion mutant from the original FM3A/0 cell line. Thus, whereas prolonged GCV drug pressure converted the FM3ATK To circumvent the mutational loss of sensitivity to GCV, Moolten and colleagues 15, 21 have suggested that the introduction of two or more TK genes per cell could be a successful approach. This would increase the number of mutations required to abolish all HSV-1 TK activity. However, our Southern blot analysis revealed that at least four TK gene copies were present in the genome of the original FM3ATK − /HSV-1 TK + cell line, and yet, drug-resistant FM3ATK − /HSV-1 TK + cell lines could easily be selected. It cannot be excluded, however, that only one of these TK genes is functionally expressed in the wild-type TK gene-transfected tumor cell line. The rather easy appearance of resistance during GCV or BVDU treatment of HSV-1 TK gene-transfected cells indicates the importance of the bystander effect. This is the killing of non-transfected bystander tumor cells by drug metabolites formed in nearby TK gene-transfected cells, 6 ,22 most likely due to metabolic cooperation, ie the transfer of phosphorylated drug metabolites through intercellular gap junctions. 23, 24 Indeed, investigators have shown that GCV-resistant tumor cells appearing after GCV administration to tumor-bearing animals did so only with tumor cell lines exhibiting a poor bystander effect. 16, 25 In tumor cells with an efficient bystander effect, the small percentage of GCV-resistant cells apparently were killed by the neighboring GCV-sensitive (functional TK-expressing) tumor cells. Also, Barba et al 26 found resistant colonies in vitro after GCV-treatment of HSV-1 TK gene-transfected tumor cell cultures, whereas in vivo, all tumor-bearing animals remained tumor-free after GCV treatment. Thus, the efficiency of the bystander cell killing in a particular cell line seems to affect the development of GCV-resistant tumor cell colonies. In this respect, it should be kept in mind that the FM3ATK − /HSV-1 TK + cells used in this study are suspension cells and hence, insensitive to bystander cell killing.
In Cells were maintained in RPMI 1640 culture medium supplemented with 10% heat-inactivated fetal calf serum (Integro, Zaandam, The Netherlands), 2 m l-glutamine (Gibco, Paisley, UK), 0.075 % (w/v) NaHCO 3 (Gibco), 0.5 l/ml geomycine (Gentamycin, 40 mg/ml, ScheringPlough, Madison, NJ, USA) and 0.5 l/ml Amphotericin B (Fungizone, 5 mg/ml, Bristol-Myers Squibb, Brussels, Belgium), and incubated at 37°C in a humidified CO 2 -controlled atmosphere. FM3ATK − /HSV-1 TK + cells resistant to BVDU or GCV, and FM3ATK
− cells resistant to BVDU were obtained by growing the cells in the presence of escalating concentrations of the compounds, as outlined in Figures 1 and 8 . To determine the growth rate of the cells, 6 × 10 4 cells were suspended in growth medium in 200-l wells of microtiter plates and incubated at 37°C in a humidified CO 2 -controlled atmosphere. At different time intervals, the cell numbers were evaluated using a Coulter Counter (Harpenden, UK). For DNA, RNA and TK activity analysis, resistant cell lines were cloned by growing diluted cell suspensions in microtiter plates in the presence of BVDU or GCV. All individual clones exhibited the same characteristics with regard to growth and sensitivity for nucleoside analogues as the cell line they originated from. 
Cytostatic activity of antiviral compounds
The methods for evaluating the cytostatic activity of the test compounds against the various FM3A cells were reported previously. 3, 4 Briefly, 6 × 10 4 cells suspended in growth medium were allowed to proliferate in 200-l wells of microtiter plates in the presence of five-fold dilutions of the test compounds at 37°C in a humidified CO 2 -controlled atmosphere. After 48 h, the number of cells was counted in a Coulter Counter. The IC 50 -value was defined as the compound concentration required to inhibit cell proliferation by 50%.
Southern blot analysis
A digoxigenin-labelled probe specific for HSV-1 TK was prepared by PCR in the presence of digoxigenin-11-2Ј-deoxyuridine-5Ј-triphosphate (Roche Diagnostics, Mannheim, Germany), on the pEGFP-N1-HSV-1 TK construct that has been described before. 27 Primers (5Ј-GAGGAATTCATGGCTTCGTACCCCGGCCATC-3Ј and 5Ј-CTCGTCGACAGGTTAGCCTCCCCCATCTCCCG-3Ј) were from KEBO Lab (Stockholm, Sweden). Total cellular DNA was isolated from the FM3A cell lines using QIAmp Blood Kit (Qiagen, Hilden, Germany). Five micrograms of each DNA preparation was cut (BamHI, or BamHI + Sal1, or BamHI + EcoRI, or BamHI + HpaII, or BamHI +MspI; Promega, Madison, WI, USA) and separated on a 0.9% agarose gel. Capillary blotting on a Hybond-N membrane (Amersham, Uppsala, Sweden) was performed overnight. After UV-cross linking, the membrane was hybridized with the digoxigenin-labelled probe by overnight incubation at 42°C. The membrane was then treated with blocking reagent (Roche Diagnostics) and incubated with alkaline phosphataseconjugated anti-digoxigenin antibody (Roche Diagnostics).
Chemiluminescence detection was performed using disodium 3-(4-methoxyspiro (1,2-dioxetane-3,2Ј-(5Ј-chloro)tricyclo[3.3.1.1]decan)-4-yl) phenyl phosphate (CSPD; Roche Diagnostics).
PCR and RT-PCR
Total RNA was isolated from wild-type and mutant FM3ATK − /HSV-1 TK cell lines using RNeasy Mini Kit (Qiagen) as described by the supplier, and subsequently treated with DNaseI (Roche Diagnostics). For the RT reaction, we used RAV-2 reverse transcriptase (RT) and human placenta RNAse inhibitor from Amersham, oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and dNTPs from Gibco, and 2 g heat-denatured total cellular RNA. For the PCR reaction, we used SuperTaq (HT Biotechnology, Cambridge, UK), TK primers (5Ј-GAGGAATTCATGGCTTCGTACCCC GGCCATC and 5Ј-CTCGTCGACAGGTTAGCCTCCCCC ATCTCCCG) from KEBO Lab, ␤-actin primers (5Ј-ATCCTCACCCTGAAGTACCCCA-3Ј and 5Ј-GAAGGT CTCAAACATGATCTGGGT-3Ј) and dNTPs from Gibco. The amounts of RT reaction product or the amounts of total cellular DNA that were used in the PCR reactions were adjusted so as to give rise to comparable levels of ␤-actin fragment amplification. The ␤-actin primers were a kind gift from Leen De Bolle (Rega Institute for Medical Research, Leuven, Belgium).
Enzyme extract preparation and TK assay Cell pellets from wild-type and mutant FM3ATK − /HSV-1 TK cell lines were washed once with PBS and once with suspension buffer (0.1 m Tris-HCl, pH 8.0, supplemented with 0.02 m ␤-mercaptoethanol). Finally, cells were resuspended in suspension buffer at a concentration of 10 8 cells/ml. Cell suspensions were sonicated three times for 10 s, followed by ultracentrifugation (25 000 r.p.m., 45 min). Extracts were dialysed against 1000 volumes 10 mm Tris-HCl, pH 8.0 using Slide-A-Lyzer (Pierce Chemical, Rockford, IL, USA), stored in aliquots at −70°C and assayed for TK activity by a modification of the radiochemical method previously described by Ives and Wang. 28 The standard reaction mixture contained 2.5 mm MgCl 2 , 10 mm dithiothreitol, 1 mg/ml bovine serum albumin, 2.5 mm ATP, 10 mm NaF, [methyl-3 H]dThd (25, 10 and 2.5 m; 1.2 Ci), and 5 l cell extract dilution in a total reaction mixture of 50 l of 50 mm Tris-HCl, pH 8.0. The reaction mixture was incubated at 37°C for 0.5, 2 and 5 h, and the reaction terminated by spotting an aliquot of 30 l on to DE-81 discs (Whatman, Maidstone, UK). The discs were instantly immersed in ethanol (70%) and thoroughly washed. Finally, filters were dried and assayed for radioactivity.
